PacBio Q4 rev $39.2M (-33% YoY), $90M impairment, non-GAAP loss $55.3M

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

2024-FY EPS reported -$1.59 revenue$154,014,000

Revenue $39.2M vs $58.4M prior year; instrument revenue fell to $15.3M from $35.1M.
GAAP net income of $3.6M includes $154.4M gain on debt restructuring; non-GAAP net loss $55.3M ($0.20 loss per share).
Preliminary non-cash impairment charges of ~$90.1M for goodwill and IPR&D due to macroeconomic headwinds.
Cash $389.9M, down from $631.4M; convertible note exchange reduced principal by $259M.
Launched Vega benchtop platform and SPRQ chemistry enabling sub-$500 genome, with 23 Revio and 7 Vega systems shipped.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.